875754-99-7

Upstream product

• 485-89-2 oxycinchophen 
• 875754-97-5 2-phenyl-3-(phenylmethoxy)quinoline-4-carboxylic acid 
• 875754-98-6 2-phenyl-3-(phenylmethoxy)-4-quinolinecarboxylic acid, 2-(methoxycarbonyl)-2-phenylhydrazide 

Downstream Products

• 914654-35-6 methyl 2-{[3-(2-methoxy-2-oxoethoxy)-2-phenylquinolin-4-yl]carbonyl}-1-phenylhydrazinecarboxylate 
• 914654-33-4 Methyl 2-({3-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-2-phenylquinolin-4-yl}carbonyl)-1-phenylhydrazinecarboxylate 
• 914656-00-1 methyl 2-{[3-(2-hydroxyethoxy)-2-phenylquinolin-4-yl]carbonyl}-1-phenylhydrazinecarboxylate 
• 914656-05-6 Methyl 2-{[3-(2-Bromoethoxy)-2-phenylquinolin-4-yl]carbonyl}-1-phenylhydrazinecarboxylate 

Relevant academic research and scientific papers

Quinoline derivatives as neurokinin receptor antagonists

The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R1, R2, R3, R4, R5, X, Y and Z are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.

N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists

A new class of potent NK3R antagonists based on the N′,2-diphenylquinoline-4-carbohydrazide core is described. In an ex vivo assay in gerbil, the lead compound 2g occupies receptors within the CNS following oral dosing (Occ90 30 mg/k

QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS

The present invention relates to substituted quinoline-4-carboxylic acid hydrazides defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors.